All In Biotech

Drug Trial Radar · NCT03737214

A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease

A Multi-center, Open-label, Uncontrolled, Single-arm, Extension Study to Determine the Long-term Safety and Tolerability of Oral Lucerastat in Adult Subjects With Fabry Disease

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

107

Actual

Start

Dec 18, 2018

Primary completion

Aug 31, 2026

Study completion Oct 6, 2026

Sponsor

Lead sponsor
Idorsia Pharmaceuticals Ltd.Industry
Sponsor type
Industry
First posted
Nov 9, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry disease. This study includes a sub-study evaluating kidney Gb3 inclusions (and other histologic lesions) in male participants with classic Fabry disease who have been treated for at least 2 years with lucerastat monotherapy in study ID-069A302.

Conditions

  • Fabry Disease

Interventions

  • LucerastatDrug

    Administered in hard gelatin capsules containing 250 mg of lucerastat.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment-emergent adverse events (AEs)Time frame: From enrollment to Follow-up 1 (FU1) visit; duration: for up to 10 years including 1 month Follow-up

Locations

42 sites in 13 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham - Nephrology Research Clinic

    Birmingham, Alabama

  • University of California Irvine

    Irvine, California

  • UCSF Benioff Children's Hospital Oakland

    Oakland, California

  • University of Florida Clinical and Translational Science Institute, UF Clinical Research Center

    Gainesville, Florida

  • Rush University Medical Center - Dept of Pediatrics

    Chicago, Illinois

  • University of Iowa Stead Family Children's Hospital - Division of Medical Genetics

    Iowa City, Iowa

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Infusion Associates

    Grand Rapids, Michigan

  • University of Pennsylvania - Dept of Medicine

    Philadelphia, Pennsylvania

  • Greenwood Genetics Center

    Greenville, South Carolina

  • Renal Disease Research Institute LLC

    Dallas, Texas

  • Baylore University Medical Center

    Dallas, Texas

  • University of Utah - Division of Medical Genetics, Clinical Genetics Research

    Salt Lake City, Utah

  • Lysosomal and Rare Disorders Research and Treatment Center, Inc.

    Fairfax, Virginia

  • Royal Melbourne Hospital - Department of Nephrology

    Parkville, Australia

  • Royal Perth Hospital, Department of Nephrology

    Perth, Australia

  • Medizinische Universität Wien, Universitätsklinik für Innere Medizin III, Klinische Abteilung für Nephrologie und Dialyse

    Vienna, Austria

  • University Hospital Ghent (UZ Ghent)

    Ghent, Belgium

  • University Hospital Gasthuisberg, Leuven (UZ Leuven)

    Leuven, Belgium

  • University of Calgary - Heritage Medical Research Clinic

    Calgary, Canada

  • London Health Sciences CTR, Victoria Hospital

    London, Canada

  • Research Center, Hôpital du Sacré-Coeur de Montréal

    Montreal, Canada

  • Vancouver General Hospital - Adult Metabolic Diseases Clinic

    Vancouver, Canada

  • Children's Hospital Research Institute of Manitoba

    Winnipeg, Canada

  • Raymond Poincaré Hosp - Med Genetics Dept

    Garches, France

  • Universitätsmedizin Berlin - Charité Campus Mitte

    Berlin, Germany

  • SphinCS GmbH

    Höchheim, Germany

  • Nephrologicum Markgräflerland MVZ GmbH

    Müllheim, Germany

  • Universitätsklinikum Würzburg

    Würzburg, Germany

  • Hospital Academisch Medisch Centrum - Department of Internal Medicine, Div. Endrocrinology and Metabolism

    Amsterdam, Netherlands

  • Haukeland University Hospital

    Bergen, Norway

  • Clinic of Immunological Diseases and Blood Coagulability Cracow University Hospital

    Krakow, Poland

  • Narodowy Instytut Kardiologii Stefana kardynała Wyszyńskiego - Państwowy Instytut Badawczy

    Warsaw, Poland

  • The Children's Memorial Health Institute, Department of Pediatric, Nutrition and Metabolic Diseases

    Warsaw, Poland

  • Vall d'Hebron University Hospital - Unit of Inherited Metabolic Disorders and Rare Diseases

    Barcelona, Spain

  • Hospital Universitari de Bellvitge / Nephrology Dpt

    Barcelona, Spain

  • Hospital Universitario Ramon y Cajal. Servicio de Medicina Interna

    Madrid, Spain

  • Hospital Quironsalud Zaragoza

    Zaragoza, Spain

  • Psychiatrische Universitätsklinik Zürich

    Zurich, Switzerland

  • Royal Free London NHS Foundation Trust Lysosomal Storage Disorder Unit; Department of Hematology

    London, United Kingdom

Showing 40 of 42 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.